Codexis Reports Q2 2026 Financial Results with Revenue of $14.9 Million

Codexis, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $14.9 million, a slight decrease of 3% compared to $15.3 million in the same period of 2025. The company's product revenue, however, saw a significant increase of 79%, rising to $13.2 million from $7.4 million year-over-year, driven by higher sales of enzymes used in pharmaceutical manufacturing. In contrast, research and development revenue dropped sharply by 79% to $1.7 million, primarily due to the absence of milestone payments that had been recognized in the previous year. For the first half of 2026, total revenues increased by 32% to $30.2 million, compared to $22.9 million in the first half of 2025.

The company's operating expenses decreased by 7% to $26.1 million in the second quarter, down from $28.2 million in the prior year. This reduction was attributed to lower research and development costs and decreased selling, general, and administrative expenses, which fell by 11% and 16%, respectively. As a result, Codexis reported a net loss of $12.0 million for the quarter, an improvement from the $13.3 million loss in the same quarter of 2025. For the six months ended June 30, 2026, the net loss was $20.7 million, significantly reduced from $34.0 million in the prior year.

In terms of strategic developments, Codexis has been actively enhancing its ECO Synthesis manufacturing platform, which focuses on the enzymatic synthesis of RNA interference therapeutics. The company has entered partnerships with several contract development and manufacturing organizations (CDMOs) to evaluate and scale up its enzymatic tools for commercial production. Additionally, Codexis signed a lease for a new 34,000-square-foot GMP manufacturing facility in Hayward, California, aimed at expanding its capabilities in GMP manufacturing of siRNA and other oligonucleotides.

Operationally, Codexis reported a decrease in cash and cash equivalents, which stood at $27.2 million as of June 30, 2026, down from $50.8 million at the end of 2025. The company’s working capital also declined to $48.4 million from $71.5 million. The reduction in cash was primarily due to net cash used in operating activities, which totaled $22.8 million for the first half of 2026, a decrease from $31.8 million in the same period of 2025. The company continues to manage its cash flow carefully, focusing on funding its ongoing operations and capital expenditures.

Looking ahead, Codexis remains optimistic about its growth prospects, particularly with the anticipated expansion of its ECO Synthesis platform and the new GMP facility. The company expects that these developments will enhance its ability to meet customer demands and support clinical trial supply requirements. However, it acknowledges the need for additional capital to support its strategic initiatives and may pursue various funding options, including equity offerings and collaborations, to ensure sufficient resources for future growth.